Find the Perfect Plan for Your Investment Journey
N
Latest price
52 Week Range
A$8.61 - A$24.00
Next Earnings Date
Aug 25 2025 (Estimate)
Next Earnings Date
Aug 25 2025 (Est.)
Latest price
Market Cap | A$1.42B |
EV | A$1.20B |
Shares Outstanding | 125.81M |
Beta | 1.85 |
Analyst Rating | BUY |
Analyst Target Price | A$24.97 |
P/E 2025E | 63.07x |
P/Revenue 2025E | 20.63x |
Revenue | 288.50% |
EPS | - |
Operating Cash Flow | -4.20% |
Free Cash Flow | -4.20% |
Revenue | -11.60% |
EPS | -19.80% |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | 32.60% |
ROE 2025E | 5.84% |
ROCE 2024 | 49.92% |
DPS 2025E | A$0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
N
Neuren Pharmaceuticals Limited
NEU
Sector
Healthcare
Industry
Biotechnology
CEO
Pilcher, Jonathan
Employees
8
Website
www.neurenpharma.comIPO Date
2005-02-01
Headquarters
697 Burke Road, Suite 201, Camberwell, Victoria, 3124, Australia
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved